Lundquist investigator Chang's study in JAMA Internal Medicine

LOS ANGELES (April 13, 2021) -- The Lundquist Institute (TLI) Investigator Dong W. Chang, MD, and his colleagues' study on critically ill patients and ICU treatments was published in JAMA Internal Medicine. The study - "Evaluation of Time-Limited Trials Among Critically Ill Patients with Advanced Medical Illnesses and Reduction of Nonbeneficial ICU Treatments" - found that training physicians to communicate with family members of critically ill patients using a structured approach, which promotes shared decision-making, improved the quality of family meetings. This intervention was associated with reductions in invasive ICU treatments that prolonged suffering without benefit for patients and their families.

"Invasive ICU treatments are frequently delivered to patients who have very little chance of benefit. This leads to prolonged suffering for our patients and their families. We believed that poor communication was one of the key causes for this problem. In our study, we found that training physicians to use time-limited trials of ICU treatments engages families to make decisions together with the physicians and reduces unnecessary ICU treatments." said Dr. Chang.

The published study can be assessed here.

INFORMATION:

JAMA doi: 10.1001/jamainternmed.2021.1000

Media Contact for The Lundquist Institute: Max Benavidez max.benavidez@lundquist.org 310-200-2682

About The Lundquist Institute: Research with reach The Lundquist Institute is an engine of innovation with a global reach and a 69-year reputation of improving and saving lives. With its new medical research building, its state-of-the-art incubator, "BioLabs at The Lundquist," existing laboratory and support infrastructure, and the development of a new 15-acre business tech park, The Lundquist Institute serves as a hub for the Los Angeles area's burgeoning biotech scene. The research institute has over 100 principal investigators (PhDs, MDs, and MD/PhDs) working on more than 600 research studies, including therapies for numerous, and often fatal orphan diseases.